Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RAPP Stock Forecast 2026-2027
$27.42
Current Price
$1.31B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RAPP Price Targets
+191.8%
To High Target of $80.00
+82.3%
To Median Target of $50.00
+45.9%
To Low Target of $40.00
RAPP Price Momentum
-3.1%
1 Week Change
-7.4%
1 Month Change
+105.5%
1 Year Change
-9.6%
Year-to-Date Change
-35.1%
From 52W High of $42.27
+326.4%
From 52W Low of $6.43
📊 TOP ANALYST CALLS
Did RAPP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rapport is one of their latest high-conviction picks.
Latest RAPP Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, RAPP has a bullish consensus with a median price target of $50.00 (ranging from $40.00 to $80.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $27.42, the median forecast implies a 82.3% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason N. Butler at Citizens, projecting a 191.8% upside. Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 45.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPP Analyst Ratings
9
Buy
0
Hold
0
Sell
RAPP Price Target Range
Low
$40.00
Average
$50.00
High
$80.00
Current: $27.42
Latest RAPP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $40.00 |
| Dec 8, 2025 | BTIG | Kambiz Yazdi | Buy | Reiterates | $47.00 |
| Nov 19, 2025 | BTIG | Kambiz Yazdi | Buy | Initiates | $47.00 |
| Nov 7, 2025 | Citizens | Jason N. Butler | Market Outperform | Maintains | $80.00 |
| Sep 16, 2025 | Truist Securities | Joon Lee | Buy | Initiates | $44.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $34.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $31.00 |
| Jul 8, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $28.00 |
| Apr 8, 2025 | JMP Securities | Jason Butler | Market Outperform | Initiates | $28.00 |
| Oct 18, 2024 | Jones Trading | Justin Walsh | Buy | Initiates | $42.00 |
| Jul 2, 2024 | Jefferies | Andrew Tsai | Buy | Initiates | $35.00 |
| Jul 2, 2024 | Stifel | Paul Matteis | Buy | Initiates | $35.00 |
| Jul 2, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $N/A |
Rapport Therapeutics Inc. (RAPP) Competitors
The following stocks are similar to Rapport based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RAPP
Rapport Therapeutics
mkt cap
1.38B
Rapport Therapeutics Inc. (RAPP) Financial Data
Rapport Therapeutics Inc. has a market capitalization of $1.31B with a P/E ratio of 21.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -23.4%.
Valuation Metrics
Market Cap
$1.31B
Enterprise Value
$790.46M
P/E Ratio
21.2x
PEG Ratio
0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+39.3%
Current Ratio
36.4x
Debt/Equity
2.3x
ROE
-23.4%
ROA
-15.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rapport Therapeutics Inc. (RAPP) Business Model
About Rapport Therapeutics Inc.
What They Do
Develops neurological medicines for unmet medical needs.
Business Model
Rapport Therapeutics Inc. employs a biotechnology model focused on the discovery and development of therapies for neurological disorders. The company generates revenue through the creation of new drug candidates, leveraging its expertise in precision neuroscience, medicinal chemistry, and genetics to address specific neurological targets.
Additional Information
The company aims to improve treatments for conditions like epilepsy, neuropathic pain, and psychiatric disorders. With a holistic approach to drug development, Rapport Therapeutics is positioned as a key innovator in the biotech industry, contributing to advancements in the pharmaceutical market and improving patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Mr. Abraham N. Ceesay M.B.A.
Country
United States
IPO Year
N/A
Website
www.rapportrx.comRapport Therapeutics Inc. (RAPP) Latest News & Analysis
Latest News
Quick Summary
Rapport Therapeutics (Nasdaq: RAPP) plans to start a Phase 3 trial for RAP-219 targeting focal onset seizures in Q2 2026, while expanding its epilepsy portfolio and advancing other pipeline projects.
Why It Matters
FDA approval for RAP-219's Phase 3 trials boosts Rapport Therapeutics' growth prospects, expanding its epilepsy portfolio and enhancing investor confidence in its pipeline advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
24 days ago
Quick Summary
Cormorant Asset Management increased its stake in Rapport Therapeutics by 251,600 shares, raising its position value by $61.38 million, now 0.31% of its 13F assets.
Why It Matters
Cormorant's significant investment in Rapport Therapeutics signals confidence in the company's potential, which could influence market sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Rapport Therapeutics, Inc. (Nasdaq: RAPP) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m., focusing on precision medicines for neurological disorders.
Why It Matters
Rapport Therapeutics' presentation at a major healthcare conference could generate investor interest and influence stock performance, especially regarding its drug development progress.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (RAPP) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
The mention of Rapport Therapeutics as a potential top stock pick indicates growing interest, which could drive momentum and influence stock performance, attracting more investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
RAP-219 Phase 2a analysis indicates early onset of action and consistent median response throughout treatment, with efficacy unaffected by disease severity.
Why It Matters
Positive Phase 2a data for RAP-219 indicates strong efficacy and reliability, suggesting potential for approval and market success, which can boost investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (RAPP) has a consensus price target suggesting a 75% upside potential, supported by an upward trend in earnings estimate revisions.
Why It Matters
A 75% upside potential suggests significant gains for Rapport Therapeutics, Inc. (RAPP), while rising earnings estimates indicate positive momentum, making it a potential buy.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About RAPP Stock
What is Rapport Therapeutics Inc.'s (RAPP) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Rapport Therapeutics Inc. (RAPP) has a median price target of $50.00. The highest price target is $80.00 and the lowest is $40.00.
Is RAPP stock a good investment in 2026?
According to current analyst ratings, RAPP has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPP stock?
Wall Street analysts predict RAPP stock could reach $50.00 in the next 12 months. This represents a 82.3% increase from the current price of $27.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapport Therapeutics Inc.'s business model?
Rapport Therapeutics Inc. employs a biotechnology model focused on the discovery and development of therapies for neurological disorders. The company generates revenue through the creation of new drug candidates, leveraging its expertise in precision neuroscience, medicinal chemistry, and genetics to address specific neurological targets.
What is the highest forecasted price for RAPP Rapport Therapeutics Inc.?
The highest price target for RAPP is $80.00 from Jason N. Butler at Citizens, which represents a 191.8% increase from the current price of $27.42.
What is the lowest forecasted price for RAPP Rapport Therapeutics Inc.?
The lowest price target for RAPP is $40.00 from Douglas Tsao at HC Wainwright & Co., which represents a 45.9% increase from the current price of $27.42.
What is the overall RAPP consensus from analysts for Rapport Therapeutics Inc.?
The overall analyst consensus for RAPP is bullish. Out of 9 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are RAPP stock price projections?
Stock price projections, including those for Rapport Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:45 PM UTC